Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.